Back to Search
Start Over
COVID symptoms, testing, shielding impact on patientāreported outcomes and early vaccine responses in individuals with multiple myeloma.
- Source :
-
British Journal of Haematology . Jan2022, Vol. 196 Issue 1, p95-98. 4p. - Publication Year :
- 2022
-
Abstract
- All patients who had had a previous infection had a robust antibody response to the first dose of COVID-19 vaccine and 60% of patients had an optimal immune response to the first dose of COVID-19 vaccination. COVID symptoms, testing, shielding impact on patient-reported outcomes and early vaccine responses in individuals with multiple myeloma Keywords: myeloma; COVID-19; vaccination; wellbeing; shielding EN myeloma COVID-19 vaccination wellbeing shielding 95 98 4 12/27/21 20220101 NES 220101 Patients with myeloma have been shielded and self-isolated since the start of the COVID-19 pandemic, due to the concern for and subsequent reports of higher risk of severe COVID-19 disease and mortality.1 In addition, guidelines have encouraged attenuation of myeloma therapeutics or a switch to oral therapies, ostensibly to reduce hospital foot-fall, facilitate shielding and potentially to limit further treatment-related immune suppression.2 Myeloma requires ongoing immune-suppressive chemotherapy, frequent medical visits and has previously demonstrated universally poor response to vaccinations.3 The protective titre of antibodies required to prevent re-infection is unclear, as is the ability to protect patients from SARS-CoV-2 virus variants of concern (VoC). [Extracted from the article]
- Subjects :
- *VACCINE effectiveness
*MULTIPLE myeloma
*COVID-19
*DISEASE remission
Subjects
Details
- Language :
- English
- ISSN :
- 00071048
- Volume :
- 196
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- British Journal of Haematology
- Publication Type :
- Academic Journal
- Accession number :
- 154291370
- Full Text :
- https://doi.org/10.1111/bjh.17764